Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Related News
Insights
Company Spotlight
A clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with diseases of the eye, salivary gland and central nervous system.
Latest News & Features of interest to Vertex Pharmaceuticals
Pharmaceutical
Tokyo-based Renalys Pharma, a late-stage clinical biopharmaceutical company, has successfully completed a $43.5 million series A financing. 17 July 2024
Pharmaceutical
Lexicon Pharmaceuticals announced that the US Food and Drug Administration (FDA) has acknowledged the resubmission of its New Drug Application (NDA) for Zynquista (sotagliflozin) 17 July 2024
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of Ohtuvayre (ensifentrine). 17 July 2024
Pharmaceutical
A licensing deal between CSL Vifor and Akebia Therapeutics has been terminated, as the commercial launch of Vafseo (vadadustat) gets underway. 16 July 2024
Biotechnology
AbbVie’s market leadership, driven by its flagship disease-modifying antirheumatic drug Humira (adalimumab), faced a significant test with the 2023 loss of patent protection. 16 July 2024
Pharmaceutical
Sionna Therapeutics today announced it has acquired exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds through a license agreement with pharma major AbbVie. 16 July 2024
Pharmaceutical
Privately-held inflammatory disease specialist SFA Therapeutics has appointed James Kirwin as chief operating officer. 16 July 2024
Pharmaceutical
CordenPharma is making a record investment of around 900 million euros ($982 million) over the next three years in expanding its peptide platform. 16 July 2024
Pharmaceutical
The wait for Eli Lilly's Mounjaro (tirzepatide) has got longer in India. 15 July 2024
Pharmaceutical
The number of diagnosed chronic kidney disease (CKD) cases in seven major markets is expected to rise from around 21 million to 23 million by 2033. 15 July 2024
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
29 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze